P451 Short-and long-term effectiveness of ustekinumab in patients with Crohn’s disease: real-world data from a German IBD cohort
A. Kubesch1, L. Rueter1, K. Farrag2, T. Krause3, K. Stienecker4, J. Hausmann1, N. Filmann5, A. Dignass6, J. Stein2, I. Blumenstein1
1Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt a. M., Germany, 2Crohn- und Colitis Zentrum, Rhein-Main, Frankfurt a. M., Germany, 3R. Rautenkranz- T. Krause, Gastroenterologie Opernstraße- CED-Schwerpunktpraxis, Kassel, Germany, 4Dr. Stienecker, CED Schwerpunktpraxis, Fulda, Germany, 5Institute of Biostatistics and Mathematical Modeling, University Hospital Frankfurt, Frankfurt a. M, Germany, 6Department of Internal Medicine I, Agaplesion Markus Krankenhaus, Frankfurt a. M., Germany
Background
The IL-12/23 inhibitor ustekinumab (UST) opened up new treatment options for patients with Crohn’s disease (CD). Due to the recent approval, Real-World German data on long-term efficacy and safety are lacking. This study aimed to assess the clinical course of CD patients under UST therapy and to identify potential predictive markers.
Methods
Patients with CD receiving UST treatment in three hospitals and two outpatient centres were included and retrospectively analysed. Rates for short- and long-term remission and response were analysed with the help of clinical (Harvey–Bradshaw Index [HBI]) and biochemical (C-reactive protein [CRP], faecal calprotectin [fCal]) parameters for disease activity.
Results
Data from 180 patients were evaluated. One hundred six patients had a follow-up of at least 8 weeks and were included. 96.2% of the patients were pre-exposed to anti- TNFα agents and 34.4% to both anti-TNFα and anti-integrin. The median follow-up was 49.1 weeks (95% CI 42.03–56.25). At week 8, 51 patients (54.8%) showed response to UST, and 24 (24.7%) were in remission. At week 48, 39 (41.9%) responded to UST, and 20 patients (21.5%) were in remission. Steroid-free response and remission at week eight were achieved by 30.1%, and 19.3% of patients. At week 48, 26.9% showed steroid-free response to UST, and 15.1% of the initial patient population was in steroid-free remission. Clinical response at week 16 was independently associated with remission at week 48.
Conclusion
Our study confirms short- and long-term UST effectiveness and tolerability in a cohort of multi-treatment exposed patients.